ArticleCureus2026
Parvovirus B19-Associated Hematological Complications: Two Case Scenarios of Pure Red Cell Aplasia and Hemophagocytic Lymphohistiocytosis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parvovirus B19 (PVB19) has tropism for erythroid precursors and may cause clinically important hematological syndromes, including pure red cell aplasia (PRCA). Less commonly, it may be associated with secondary hemophagocytic lymphohistiocytosis (HLH). We report two PVB19-associated hematological presentations identified through bone marrow morphology. Case 1 was a 60-year-old woman with severe anemia, reticulocytopenia, and bone marrow erythroid hypoplasia. Giant pronormoblasts prompted PVB19 testing, and anti-PVB19 IgM was positive, consistent with PVB19-associated PRCA. Case 2 was a two-year-old girl with prolonged fever, hepatosplenomegaly, edema, ascites, and pancytopenia. Bone marrow examination showed hemophagocytosis and erythroid precursors with cytoplasmic blebs/pseudopodia. Hyperferritinemia and hypofibrinogenemia supported an HLH phenotype, and anti-PVB19 IgM was positive. Both patients received supportive care with corticosteroid-based immunomodulation; intravenous immunoglobulin was used as part of management. Hematological recovery was documented during follow-up. PVB19 should be considered in unexplained cytopenias when marrow morphology shows giant pronormoblasts, erythroid hypoplasia, or suggestive erythroid viral cytopathic changes. Early recognition may direct timely etiologic confirmation and individualized supportive or immunomodulatory treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.